- Home
- ADAP vs RENE Comparison
ADAP vs RENE Comparison
Compare ADAP & RENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADAP
- RENE
- Stock Information
- Founded
- ADAP 2008
- RENE 2021
- Country
- ADAP United Kingdom
- RENE United States
- Employees
- ADAP N/A
- RENE N/A
- Industry
- ADAP Biotechnology: Pharmaceutical Preparations
- RENE Blank Checks
- Sector
- ADAP Health Care
- RENE Finance
- Exchange
- ADAP Nasdaq
- RENE Nasdaq
- Market Cap
- ADAP 158.6M
- RENE 151.4M
- IPO Year
- ADAP 2015
- RENE 2022
- Fundamental
- Price
- ADAP $0.56
- RENE $11.72
- Analyst Decision
- ADAP Strong Buy
- RENE
- Analyst Count
- ADAP 4
- RENE 0
- Target Price
- ADAP $2.79
- RENE N/A
- AVG Volume (30 Days)
- ADAP 623.5K
- RENE 22.9K
- Earning Date
- ADAP 03-05-2025
- RENE 01-01-0001
- Dividend Yield
- ADAP N/A
- RENE N/A
- EPS Growth
- ADAP N/A
- RENE 42.92
- EPS
- ADAP N/A
- RENE 0.43
- Revenue
- ADAP $175,041,000.00
- RENE N/A
- Revenue This Year
- ADAP $204.91
- RENE N/A
- Revenue Next Year
- ADAP N/A
- RENE N/A
- P/E Ratio
- ADAP N/A
- RENE $27.04
- Revenue Growth
- ADAP 146.27
- RENE N/A
- 52 Week Low
- ADAP $0.53
- RENE $11.05
- 52 Week High
- ADAP $2.05
- RENE $11.80
- Technical
- Relative Strength Index (RSI)
- ADAP 40.12
- RENE 44.49
- Support Level
- ADAP $0.55
- RENE $11.65
- Resistance Level
- ADAP $0.61
- RENE $11.78
- Average True Range (ATR)
- ADAP 0.03
- RENE 0.01
- MACD
- ADAP -0.00
- RENE -0.01
- Stochastic Oscillator
- ADAP 12.14
- RENE 46.67
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.
About RENE Cartesian Growth Corporation II
Cartesian Growth Corp II is a blank check company.